Journal of Pharmaceutics & Drug Delivery ResearchISSN: 2325-9604

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Thomas Frank Author

thomas.frank@sanofi.com +49 69 305 30230

Subjects of specialization
Rheumatoid arthritis, Sinomenium

Affiliation
Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany

Biography

My name isThomas Frank-  I am from   Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany    My area of interests are Rheumatoid arthritis                                                                                                           

Publications

Research Article Open Access

Population Pharmacokinetics of Lixisenatide, a Once-Daily Human Glucagon-Like Peptide-1 Receptor Agonist, in Healthy Subjects and in Patients with Type 2 Diabetes

Author(s):

Thomas Frank

Population Pharmacokinetics of Lixisenatide, a Once- Daily Human Glucagon-Like Peptide-1 Receptor Agonist, in Healthy Subjects and in Patients with Type 2 Diabetes

Lixisenatide is a potent and selective glucagon-like peptide-1(GLP-1) receptor agonist developed for the treatment of type 2 diabetes (T2DM) with a subcutaneous once-daily regimen. The substance is currently under review for marketing authorization for the management of T2DM. In this study, the population pharmacokinetics in healthy volunteers and in adult T2DM patients was investigated.

... view more»

DOI: 10.4172/2325-9604.1000112

Abstract HTML PDF

Google Scholars / Researchers Sites

Explore SciTechnol

GET THE APP